The release of the Ocular Hypertension Pipeline Review, H2 2014 was encouraging for ophthalmologic research and development teams regarding the use of Betaxolol to treat ocular hypertension. The review, published in early 2015, focused on the positive aspects of various therapies for treating ocular hypertension, with Betaxolol receiving positive feedback. The global therapeutic landscape for both preventing and treating ocular hypertension has experienced an overwhelming need for attention, particularly with the aging population worldwide. Betaxolol has been proven to be an efficacious product in various studies over the past decade, and the safety record of this targeted therapy is sound.
Defined as an increase in the pressure of the eye/eyes, ocular hypertension is not an interchangeable diagnosis with glaucoma. Ocular hypertension typically shows no damage to the structure of the eyes, or detectable vision changes in patients, which is opposite of what patients with glaucoma experience. While glaucoma often leads to optic nerve damage and progressive vision loss, ocular hypertension usually has no signs or symptoms. Statistically people who are African American and over the age of forty are diagnosed with ocular hypertension. Other known risk factors for this condition include a family history of ocular hypertension or glaucoma, diabetes and extreme nearsightedness. An increased risk of glaucoma is present for those patients diagnosed with ocular hypertension, so annual eye exams are prudent for this patient population.
While there is no cure for ocular hypertension Betaxolol is a viable option to both help prevent the development of glaucoma and keep ocular hypertension from worsening. Early treatment with Betaxolol has been favorable in prior studies for patients with ocular hypertension deemed high risk for glaucoma development. As reported in the Archives of Ophthalmology the use of Betaxolol in patients with ocular hypertension, and who were at greater for developing primary open-angle glaucoma was positive and encouraging. Over 1800 patients were enrolled in the OHTS (Ocular Hypertension Treatment Study) and the safety and effectiveness of Betaxolol was determined. With between four and eight percent of the U.S. population of adults over age forty having a diagnosis of ocular hypertension, the use of an easy to administer, twice daily eye drop like Betaxolol is prudent for both patients and practitioners alike.
The proper diagnosis of ocular hypertension is defined by an intraocular pressure reading greater than 21 mm Hg, in one or both eyes, the absence of glaucomatous defects on visual-field testing, and a normal appearance of both the optic disc and nerve fiber layers in the affected eyes. Betaxolol is available in 0.5 % eye drop and is known as the brand name Betoptic, which is marketed by Alcon Laboratories. LGM Pharma can assist clients as a supplier/distributor of the API Betaxolol, CAS # 63659-18-7 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.